Takeda Is Cutting 634 U.S. Jobs. The Real Story Is What Comes Next.

The Quiet Purge in Cambridge

Somewhere in Takeda's gleaming Cambridge, Massachusetts headquarters, 634 employees just learned their jobs have an expiration date.

Notifications went out on March 25. The actual layoffs won't hit until sometime between July 2026 and December 2027, giving the company a long runway to phase people out. Of the 634 roles, 247 are physically based in Massachusetts. The other 387 are scattered across the country but technically assigned to the Cambridge HQ.

And if you're thinking "well, 634 isn't that many for a global pharma company," you'd be right in isolation. But isolation isn't the right lens here.

This Isn't Round One. It's More Like Round Five.

Takeda has been trimming its U.S. workforce like a gardener who can't stop pruning. The company cut nearly 1,500 employees across the U.S. and Austria during 2024 and early 2025. Then came 137 more layoffs in October 2025. Another 243 field-based roles vanished in January 2026, tied to the patent cliff on Trintellix, an antidepressant losing its exclusivity moat.

Now add 634 more to the tally. That's roughly 2,500 positions eliminated in about two years.

Picture a restaurant that keeps firing servers while promising the kitchen is about to cook something incredible. At some point, you start wondering: is the kitchen actually ready, or are they just running out of money for the front of house?

The $1.3 Billion Bet

Takeda says the restructuring is about redirecting resources, not shrinking them. The target: more than 200 billion yen (roughly $1.3 billion) in annualized savings by fiscal year 2028. That's a massive number, and it comes with a massive price tag. The restructuring itself is expected to cost around 150 billion yen ($940 million) in FY2026 alone.

So you're spending nearly a billion dollars to eventually save $1.3 billion per year. On paper, that math works beautifully. In practice, restructurings are messy, slow, and full of hidden costs: lost institutional knowledge, disrupted teams, recruiting expenses when you inevitably need to rehire some of those roles.